A cancer vaccine developed by Moderna and Merck has shown promising results in a trial. The vaccine, which uses mRNA technology, was found to prevent melanoma from returning.

The study also achieved a secondary objective, which was to prevent the cancer from spreading to other parts of the body. This goal was met, according to the trial results.

Further details about the trial and its findings are available from the source. The outcome of this study suggests potential for the vaccine in preventing cancer recurrence and spread.